Registration Dossier

Diss Factsheets

Toxicological information

Carcinogenicity

Currently viewing:

Administrative data

Description of key information

In REACH Annex X column II it is stated:

“A carcinogenicity study may be proposed by the registrant or may be required by the Agency in accordance with Articles 40 or 41 if:

– the substance has a widespread dispersive use or there is evidence of frequent or long-term human exposure; and

– the substance is classified as mutagen category 3 or there is evidence from the repeated dose study(ies) that the substance is able to induce hyperplasia and/or pre-neoplastic lesions.”

AKD has a wide dispersive use however AKD is not classified as mutagen category 3 and there is no evidence from repeated dose studies that AKD is able to induce hyperplasia and/or pre-neoplastic lesions.

Key value for chemical safety assessment

Justification for classification or non-classification

Additional information